December 12, 2025

Contracts signed for Heidelberg-Mannheim hospital network

Contracts signed for Heidelberg-Mannheim hospital network

It’s now official: the alliance between the two university hospitals in Heidelberg and Mannheim can start as planned on January 1 and begin its work. Press release from the Baden-Württemberg Ministry of Science, Research, and the Arts.

Full Text in German below.


Verträge zum Klinikverbund Heidelberg-Mannheim unterzeichnet

Nun ist es offiziell: Der Verbund zwischen den beiden Universitätsklinika Heidelberg und Mannheim kann zum 1. Januar wie geplant starten und seine Arbeit beginnen. Pressemitteilung des Ministeriums für Wissenschaft, Forschung und Kunst Baden-Württemberg

Die Verträge sind gestern, 8. Dezember, in Stuttgart im Ministerium für Wissenschaft, Forschung und Kunst (MWK) unterschrieben worden. Zu den Unterzeichnerinnen und Unterzeichnern gehörten neben den Leitungen der beiden Klinika Wissenschaftsministerin Petra Olschowski, der Mannheimer Oberbürgermeister Christian Specht und die Rektorin der Universität Heidelberg, Professorin Frauke Melchior.

„Sehr gute Nachricht für das Land Baden-Württemberg“

Die Universitätsklinik Heidelberg übernimmt damit knapp 90 Prozent der Anteile der Universitätsklinik Mannheim. „Das ist eine sehr gute Nachricht für die beiden Klinika und für das Land Baden-Württemberg“, sagte Wissenschaftsministerin Olschowski. „Mit dem Klinikverbund stärken wir weiter die nationale und internationale Sichtbarkeit unserer Spitzenmedizin und verbessern darüber hinaus die Lehre, Forschung und Versorgung der Patientinnen und Patienten im Land.“

Am 12. Januar wird es noch eine feierliche Auftaktveranstaltung zum Klinikverbund in Mannheim und Heidelberg geben.

Weitere Informationen im Internet

Diese Pressemitteilung auf der Website des MWK

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp